Windtree Therapeutics

Windtree Therapeutics is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Windtree Therapeutics’ technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies.  Windtree Therapeutics’ strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Windtree Therapeutics believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy but are currently not treated.